Samuel Backenroth insider trades: NeuBase Therapeutics (NBSE) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Samuel reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 30, 2020 | NBSE | ↑ Buy | 1,000 | $6.00 | $6K | Direct | May 4, 2020 (4d) |
| Apr 10, 2017 | OHRP | ↑ Buy | 71,429 | $0.70 | $50K | Direct | Apr 13, 2017 (3d) |
| Jun 20, 2016 | OHRP | ↑ Buy | 2,468 | $2.84 | $7K | Direct | Jun 21, 2016 (1d) |
| May 23, 2016 | OHRP | ↑ Buy | 2,500 | $3.17 | $8K | Direct | May 24, 2016 (1d) |
| Feb 6, 2015 | OHRP | ↑ Buy | 1,500 | $6.75 | $10K | Direct | Feb 10, 2015 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Samuel Backenroth's insider trades
Samuel Backenroth is CFO, Treasurer & Secretary at NeuBase Therapeutics (NBSE). Since Feb 6, 2015, Samuel has reported 5 open-market purchases worth $81K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (6 filings), other transactions (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBSE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.